Scarica l'app Stockscreener
0.76
23.85%
-0.238
Pre-mercato:
.73
-0.03
-3.95%
Calidi Biotherapeutics Inc Borsa (CLDI) Ultime notizie
Calidi Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks
Top Penny Stocks To Add to Your Watchlist – July 9th - Defense World
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Calidi Biotherapeutics: Redefining Cancer Treatment with Breakthrough Virotherapy - AInvest
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment - The Manila Times
Breakthrough Cancer Treatment: Calidi's New Genetic Platform Targets Both Primary and Metastatic Tumors - Stock Titan
Calidi Biotherapeutics Cashes In On Warrant Agreement - Finimize
Calidi Biotherapeutics secures $4.6 million through warrant exercise By Investing.com - Investing.com Nigeria
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds - GlobeNewswire
Clinical-Stage Biotech Calidi Raises $4.6M in Fresh Capital: Accelerates Targeted Therapy Programs - Stock Titan
Crude Oil Moves Higher; RxSight Shares Plunge - Benzinga
Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May - Benzinga
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers - FinancialContent
Calidi Biotherapeutics Stock Soars 174.93% on Precision Medicine Hype - AInvest
Calidi Biotherapeutics Soars 119.7% on Cancer Trial News - AInvest
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On - Benzinga
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment - Yahoo Finance
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs – Company AnnouncementFT.com - Financial Times
Calidi Biotherapeutics (CLDI): A Breakthrough in Systemic Virotherapy and the $564B Oncology Opportunity - AInvest
Calidi Biotherapeutics (NYSE:CLDI) Shares Up 5.6% – Still a Buy? - Defense World
CLDI SEC FilingsCalidi Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Calidi Biotherapeutics Granted Patent for Cell-Based Oncolytic Virus Immunotherapy for Cancer Treatment - ACCESS Newswire
Certain Warrants of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener
Calidi Bio's Revolutionary Cancer Platform RedTail Races to Clinical Trials: CEO Reveals 2026 Timeline - Stock Titan
Millennium Management LLC Increases Stake in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Appoints Biotech Veteran Eric Poma, PhD, as CEO to Lead Next Growth Phase - citybuzz -
Jane Street Group LLC Takes Position in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025 - citybuzz -
Calidi Biotherapeutics Presents systemic oncolytic platform - GlobeNewswire
Calidi Biotherapeutics (CLDI) Showcases Innovative CLD-401 Thera - GuruFocus
Revolutionary Cancer Treatment Breakthrough: Calidi's New Systemic Delivery Platform Wows ASCO Conference - Stock Titan
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting - The Manila Times
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - The Globe and Mail
Calidi Biotherapeutics (NYSE:CLDI) Shares Down 5.3% – Time to Sell? - Defense World
Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results And Recent Operational Highlights - marketscreener.com
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewswire
Calidi Biotherapeutics Secures FDA Green Light for Cancer Trial as New CEO Reveals Q1 Financials - Stock Titan
Candel Therapeutics (NASDAQ:CADL) vs. Calidi Biotherapeutics (NYSE:CLDI) Critical Review - Defense World
Geode Capital Management LLC Buys 120,406 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
CLDICalidi Biotherapeutics Inc Latest Stock News & Market Updates - Stock Titan
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - The Globe and Mail
Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 0.3% – Time to Sell? - Defense World
Investor’s Delight: Calidi Biotherapeutics Inc (CLDI) Closes Weak at 0.65, Down -6.53 - DWinneX
Calidi (CLDI) Advances Cancer Treatment with IL15 Superagonist a - GuruFocus
Calidi Biotherapeutics Announces IL15 Superagonist as First - GlobeNewswire
Revolutionary Cancer Treatment Platform Shows Complete Tumor Elimination: First Systemic Delivery Success - Stock Titan
Calidi Biotherapeutics (CLDI) Awards Stock Option to New CEO Eri - GuruFocus
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times
Calidi Bio's Strategic Move: New CEO Secures 726K Share Options with 4-Year Performance Lock - Stock Titan
Calidi Biotherapeutics appoints new CEO By Investing.com - Investing.com South Africa
Zealand names former Lilly exec Singh as CSO - BioCentury
Calidi Biotherapeutics appoints new CEO - Investing.com
Calidi (CLDI) Appoints New CEO as Eric Poma Assumes Leadership | - GuruFocus
Calidi Biotherapeutics Appoints New CEO Eric Poma - TipRanks
Calidi Biotherapeutics Announces Chief Executive Officer Transition And Appointment Of Eric Poma, Ph.D. As CEO And Director - TradingView
Calidi Biotherapeutics Announces Chief Executive Officer - GlobeNewswire
New Calidi Bio CEO Brings $400M Funding Success Record: Strategic Shift for Cancer Treatment Pioneer - Stock Titan
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor - The Globe and Mail
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24 - The Manila Times
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24 - GlobeNewswire
2.10%
1.57%
Capitalizzazione:
|
Volume (24 ore):